Download PDF
Open Access
CC BY-NC-ND 4.0 · J Lab Physicians 2020; 12(03): 230-232
DOI: 10.1055/s-0040-1720944
Others

In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital

Authors

  • Dhruv Mamtora

    1   Department of Microbiology, S.L. Raheja Hospital, Mumbai, Maharashtra, India

  • Sanjith Saseedharan

    2   Department of Critical Care Medicine, S.L. Raheja Hospital, Mumbai, Maharashtra, India

  • Ritika Rampal

    3   Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India

  • Prashant Joshi

    4   Drug Discovery Research, Wockhardt Research Center, Aurangabad, Maharashtra, India

  • Pallavi Bhalekar

    1   Department of Microbiology, S.L. Raheja Hospital, Mumbai, Maharashtra, India

  • Jaishid Ahdal

    3   Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India

  • Rishi Jain

    3   Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India
Further Information
Also available at
  Permissions and Reprints

Abstract

Background Blood stream infections (BSIs) due to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality ranging from 10 to 60%. The current anti-MRSA agents have limitations with regards to safety and tolerability profile which limits their prolonged usage. Levonadifloxacin and its oral prodrug alalevonadifloxacin, a novel benzoquinolizine antibiotic, have recently been approved for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteremia in India.

Methods The present study assessed the potency of levonadifloxacin, a novel benzoquinolizine antibiotic, against Gram-positive blood stream clinical isolates (n = 31) collected from January to June 2019 at a tertiary care hospital in Mumbai, India. The susceptibility of isolates to antibacterial agents was defined following the Clinical and Laboratory Standard Institute interpretive criteria (M100 E29).

Results High prevalence of MRSA (62.5%), quinolone-resistant Staphylococcus aureus (QRSA) (87.5%), and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) (82.35%) were observed among bacteremic isolates. Levonadifloxacin demonstrated potent activity against MRSA, QRSA, and MR-CoNS strains with significantly lower minimum inhibitory concentration MIC50/90 values of 0.5/1 mg/L as compared with levofloxacin (8/32 mg/L) and moxifloxacin (2/8 mg/L).

Conclusion Potent bactericidal activity coupled with low MICs support usage of levonadifloxacin for the management of BSIs caused by multidrug resistant Gram-positive bacteria.

Keywords

blood stream infections - methicillin-resistant S. aureus - levonadifloxacin - quinolone-resistant S. aureus


Publication History

Article published online:
23 November 2020

© 2020. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India